A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration

Trial Profile

A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 May 2018

At a glance

  • Drugs Injectable-discogenic-cell-therapy-DiscGenics (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors DiscGenics
  • Most Recent Events

    • 16 Mar 2018 Planned End Date changed from 1 Nov 2020 to 1 Apr 2021.
    • 16 Mar 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Apr 2020.
    • 16 Mar 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top